返回
The PROTACtable genome
DOI:10.1038/s41573-021-00245-x.png)
摘要
En 中文
Targeted protein degradation by proteolysis-targeting chimeras (PROTACs) is attracting substantial interest as a therapeutic modality that could circumvent some limitations of traditional small-molecule drugs. This article presents a systematic approach to assessing the PROTAC tractability (PROTACtability) of protein targets, which could support decision-making on whether a particular target may be amenable to modulation using a PROTAC. Proteolysis-targeting chimeras (PROTACs) are an emerging drug modality that may offer new opportunities to circumvent some of the limitations associated with traditional small-molecule therapeutics. By analogy with the concept of the 'druggable genome', the question arises as to which potential drug targets might PROTAC-mediated protein degradation be most applicable. Here, we present a systematic approach to the assessment of the PROTAC tractability (PROTACtability) of protein targets using a series of criteria based on data and information from a diverse range of relevant publicly available resources. Our approach could support decision-making on whether or not a particular target may be amenable to modulation using a PROTAC. Using our approach, we identified 1,067 proteins of the human proteome that have not yet been described in the literature as PROTAC targets that offer potential opportunities for future PROTAC-based efforts.
Keyword:
SELECTIVE DEGRADATION
PROTEIN-DEGRADATION
UBIQUITIN LIGASES
SLC TRANSPORTERS
TARGETS
DISCOVERY
DEGRADER
IDENTIFICATION
COMPLEX
DESIGN
AI总结
对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
101.8
论文数:
5.1K
被引数:
5.3W
机构
引用论文
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
NATURE CHEMICAL BIOLOGY
IF13.7
Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
EBIOMEDICINE
IF10.8
Open Targets Platform: supporting systematic drug-target identification and prioritisation开放目标平台: 支持系统的药物目标识别和优先排序
NUCLEIC ACIDS RESEARCH
IF13.1

